Results 41 to 50 of about 9,592 (241)

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. [PDF]

, 2017
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three
Burra, Patrizia, Romano, Antonietta, Russo, Francesco Paolo   +2 more
core   +1 more source

Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture

Frontiers in Microbiology, 2022
We report a quantification of the decrease of effectiveness of antiviral agents directed to hepatitis C virus, when the agents are added during an ongoing infection in cell culture vs. when they are added at the beginning of the infection.
Carlos García-Crespo, Carlos García-Crespo, Lucía Vázquez-Sirvent, Lucía Vázquez-Sirvent, Pilar Somovilla, Pilar Somovilla, María Eugenia Soria, María Eugenia Soria, María Eugenia Soria, Isabel Gallego, Isabel Gallego, Ana Isabel de Ávila, Ana Isabel de Ávila, Brenda Martínez-González, Brenda Martínez-González, Antoni Durán-Pastor, Esteban Domingo, Esteban Domingo, Celia Perales, Celia Perales, Celia Perales, Celia Perales   +21 more
doaj   +1 more source

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S   +12 more
core   +3 more sources

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy

Archives of Pharmaceutical Sciences Ain Shams University, 2021
Hepatitis C virus (HCV) was first identified in 1989. The situation in Egypt is really dire. The prevalence of HCV genotype 4 (GT-4) is 14.7%. About 10% of the middle-aged population (ages 15 to 59) is infected with HCV.
Heba Elbadawy, Sara Wahdan, Ebtehal El-Demerdash   +2 more
doaj   +1 more source

Hepatitis C virus resistance to the new direct-acting antivirals [PDF]

, 2016
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella, Soriano, Vicente, Trinks, Julieta   +2 more
core   +1 more source

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. [PDF]

, 2013
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter ...
Afdhal, NH, Castera, L, Church, DR, Dee, L, Graham, C, Jacobson, IM, Litwin, AH, Mehta, SH, Muir, A, New Paradigm of HCV Therapy Meeting Participants, Poynard, T, Razavi, H, Schooley, RT, Sulkowski, MS, Talal, AH, Thomas, DL, Ward, JW, Zeuzem, S   +17 more
core   +2 more sources

Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents [PDF]

, 2017
Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality.
Burra, Patrizia, Farinati, Fabio, Floreani, Annarosa, Fogar, Paola, Franceschet, Enrica, Gambato, Martina, Nabergoj, Mitja, Pantano, G, Piva, Elisa, Plebani, Mario, Russo, FRANCESCO PAOLO, Schiavinato, Alvise, Tosato, Francesca, Zanetto, Alberto   +13 more
core   +1 more source

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Gut and Liver, 2018
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. [PDF]

, 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response ...
Benhammou, Jihane N, Bhattacharya, Debika, Dixit, Ram, Dixit, Vivek, Dong, Tien S, Han, Steven B, Jackson, Samuel, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +9 more
core   +1 more source

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon [PDF]

, 2017
Background and aims Increased levels of chemokine interferon-gamma (IFN-γ)-inducible protein-10 (CXCL10), soluble CD163 (sCD163) and soluble CD14 (sCD14) have been reported in HCV infection.
Furlan, Caterina, Iannetta, Marco, Lichtner, Miriam, Marocco, Raffaella, Mascia, Claudia, Mastroianni, Claudio Maria, Mengoni, Fabio, Pozzetto, Irene, Rossi, Raffaella, Savinelli, Stefano, Tieghi, Tiziana, Vita, Serena, Vullo, Vincenzo, Zuccalà, Paola   +13 more
core   +7 more sources